Benitec Ltd (BNIKF) 0.0700 $BNIKF
Benitec Biopharma Interim Report for the Nine Months Ended March 31, 2016
PR Newswire - Tue May 24, 3:45AM CDT
Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today lodged its Interim Report for the nine months ended March 31, 2016. The report includes the financial results and a review of operations for the period.
Benitec Biopharma to Host Corporate Update Conference Call
PR Newswire - Tue May 17, 4:00AM CDT
Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today announced that the Company will host a conference call and live audio webcast on Wednesday, 25 May 2016 at 8:00am AEST / Tuesday, 24 May 2016 at 6:00pm EDT, to provide its quarterly operational update. Interim CEO, Greg West, will provide an overview of Benitec's current and planned corporate and clinical activities.
Benitec to present at the ASGCT 2016 Annual Meeting
PR Newswire - Mon Apr 25, 7:30AM CDT
Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW), a biotechnology company developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi or 'expressed RNAi', today announced acceptance of five presentations at the 19th Annual Meeting of American Society of Gene and Cell Therapy (ASGCT) being held in Washington D.C. on May 4-7, 2016. The abstracts cover the scientific results from three of Benitec's programs: hepatitis B, OPMD and hepatitis C, with the key findings briefly summarised below.
Benitec's Hepatitis B Therapy Reduces HBV DNA by 98.5% In Vivo
PR Newswire - Tue Mar 08, 7:16AM CST
Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is pleased to announce that BB-HB-331, a DNA-directed RNA interference (ddRNAi) therapy targeting the hepatitis B virus (HBV), demonstrates robust and durable suppression of HBV in vivo following a single administration.
Neuropathic Pain Pipeline Review, H2 2015 - Therapeutics Developments from 100+ Companies
M2 - Tue Feb 09, 8:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/vlqwp7/neuropathic_pain) has announced the addition of the "Neuropathic Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuropathic Painand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Neuropathic PainOverview - Therapeutics Development - Pipeline Products for Neuropathic Pain- Overview - Pipeline Products for Neuropathic Pain- Comparative Analysis - Neuropathic Pain- Therapeutics under Development by Companies - Neuropathic Pain- Therapeutics under Investigation by Universities/Institutes - Neuropathic Pain- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Neuropathic Pain- Products under Development by Companies - Neuropathic Pain- Products under Investigation by Universities/Institutes - Neuropathic Pain- Companies Involved in Therapeutics Development Companies Mentioned - 2-BBB Medicines BV - AbbVie Inc. - Advinus Therapeutics Ltd. - Adynxx, Inc. - Aestus Therapeutics, Inc. - Affectis Pharmaceuticals AG - Allergan Plc - Amura Holdings Limited - AnaBios Corporation - Anavex Life Sciences Corp. - AngioChem Inc. - Asahi Kasei Pharma Corp. - Astellas Pharma Inc. - AstraZeneca Plc - BCN Peptides, S.A. - Benitec Biopharma Limited - BioDelivery Sciences International, Inc. - BioLineRx, Ltd. - Biomar Microbial Technologies - Bionomics Limited - Biscayne Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Can-Fite BioPharma Ltd. - Cara Therapeutics, Inc. - Catalyst Biosciences, Inc. - Cavion LLC - Cerecor Inc. - Circuit Therapeutics, Inc. - CLL Pharma - Colby Pharmaceutical Company - Convergence Pharmaceuticals Ltd. - Creabilis SA - Crinetics Pharmaceuticals, Inc. - Cytogel Pharma, LLC For more information visit http://www.researchandmarkets.com/research/vl...athic_pain
CANF: 2.62 (-0.16), BDSI: 2.39 (unch), AGN: 235.05 (-2.24), CERCU: 5.03 (-0.56), AVXL: 4.02 (-0.27), AZN: 27.58 (-0.05), CBIO: 1.60 (+0.05), ABBV: 60.01 (-0.89), BMY: 70.67 (-1.06)
Cancer Pain Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/3tjd78/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Cancer Pain Overview - Therapeutics Development - Pipeline Products for Cancer Pain - Overview - Pipeline Products for Cancer Pain - Comparative Analysis - Cancer Pain - Therapeutics under Development by Companies - Cancer Pain - Therapeutics under Investigation by Universities/Institutes - Cancer Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cancer Pain - Products under Development by Companies - Cancer Pain - Products under Investigation by Universities/Institutes - Cancer Pain - Companies Involved in Therapeutics Development - Amgen Inc. - Amorsa Therapeutics Inc. - AngioChem Inc. - Aphios Corporation - AstraZeneca Plc - BCN Peptides, S.A. - Benitec Biopharma Limited - BioDelivery Sciences International, Inc. - ChironWells GmbH - Daiichi Sankyo Company, Limited - Fujimoto Pharmaceutical Corporation - Grunenthal GmbH - GW Pharmaceuticals Plc - Hisamitsu Pharmaceutical Co., Inc. - Immupharma Plc - IntelGenx Corp. - Kolon Life Science, Inc. - Nektar Therapeutics - Neurocentrx Pharma Ltd. - Orion Oyj - Pain Therapeutics, Inc. - Pfizer Inc. - Pharmaleads - PsychoGenics, Inc. - Recordati S.p.A. - Ribomic Inc. - Virobay Inc. - WEX Pharmaceuticals Inc. - Winston Pharmaceuticals, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/3t...ancer_pain
BDSI: 2.39 (unch), PFE: 34.22 (-0.53), AMGN: 149.62 (-2.68), ZYNE: 7.55 (-0.24), NKTR: 14.85 (-0.17), AZN: 27.58 (-0.05), VBAY: (), PTIE: 2.03 (-0.06)
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review 2015
M2 - Fri Jan 29, 10:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfl587/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Wet (Neovascular / Exudative) Macular Degeneration Overview - Therapeutics Development - Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview - Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Comparative Analysis - Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies - Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes - Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies - Wet (Neovascular / Exudative) Macular Degeneration - Products under Investigation by Universities/Institutes - Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development Companies Mentioned: - Aciont Inc. - Allergan Plc - Amakem NV - Apellis Pharmaceuticals, Inc. - Apexigen, Inc. - Applied Genetic Technologies Corporatio - Avalanche Biotechnologies, Inc. - Benitec Biopharma Limited - BIOCAD - Boehringer Ingelheim GmbH - Charlesson LLC. - Chong Kun Dang Pharmaceutical Corp. - Circadian Technologies Limited - Clanotech AB - Clearside BioMedical, Inc. - Daiichi Sankyo Company, Limited - Eleven Biotherapeutics Inc. - Exonate Limited - F. Hoffmann-La Roche Ltd. - Formycon AG - GTx, Inc. - iCo Therapeutics Inc. - Icon Bioscience, Inc. - Kala Pharmaceuticals, Inc. - Mabion SA - Mitotech S.A. - Neurotech Pharmaceuticals, Inc. - Novartis AG - Ocular Therapeutix, Inc. - Ohr Pharmaceutical Inc. - Ophthotech Corp. - Oxford BioMedica Plc - PanOptica, Inc. - Pfenex Inc. - Pfizer Inc. - Quark Pharmaceuticals, Inc. - Regeneron Pharmaceuticals, Inc. - RegenxBio Inc. - RXi Pharmaceuticals Corporation - Santen Pharmaceutical Co., Ltd. - Sanwa Kagaku Kenkyusho Co., Ltd. - TRACON Pharmaceuticals, Inc. - TWi Pharmaceuticals, Inc. - Tyrogenex, Inc. - Xbrane Bioscience AB For more information visit http://www.researchandmarkets.com/research/rf...eovascular
CLSD: 7.10 (+0.10), PFE: 34.22 (-0.53), OPHT: 52.79 (-2.13), PFNX: 8.02 (-0.08), OCUL: 5.40 (-0.19), AGN: 235.05 (-2.24), GTXI: 0.61 (-0.02), OHRP: 2.68 (-0.12), AAVL: 4.14 (-0.18), TCON: 5.03 (-0.22), REGN: 354.21 (-12.31), NVS: 77.91 (+1.02)
Dry (Atrophic) Macular Degeneration therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 6:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/3cxkl2/dry_atrophic) has announced the addition of the "Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dry (Atrophic) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dry (Atrophic) Macular Degeneration Overview - Therapeutics Development - Pipeline Products for Dry (Atrophic) Macular Degeneration - Overview - Pipeline Products for Dry (Atrophic) Macular Degeneration - Comparative Analysis - Dry (Atrophic) Macular Degeneration - Therapeutics under Development by Companies - Dry (Atrophic) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes - Dry (Atrophic) Macular Degeneration - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Dry (Atrophic) Macular Degeneration - Products under Development by Companies - Dry (Atrophic) Macular Degeneration - Products under Investigation by Universities/Institutes - Dry (Atrophic) Macular Degeneration - Companies Involved in Therapeutics Development - Aciont Inc. - Acucela Inc. - Alexion Pharmaceuticals, Inc. - Alimera Sciences, Inc. - Apellis Pharmaceuticals, Inc. - Benitec Biopharma Limited - Catalyst Biosciences, Inc. - Cell Cure Neurosciences, Ltd. - Foamix Pharmaceuticals Ltd. - Genentech, Inc. - GenSight Biologics SA - GlaxoSmithKline Plc - Icon Bioscience, Inc. - MacuCLEAR, Inc. - Novartis AG - Ocata Therapeutics, Inc. - Ophthotech Corp. - pSivida Corp. - R-Tech Ueno, Ltd. - StemCells, Inc. - Sun Pharma Advanced Research Company Ltd. - U.S. Stem Cell, Inc. For more information visit http://www.researchandmarkets.com/research/3c...y_atrophic
OCAT: 8.47 (+0.01), OPHT: 52.79 (-2.13), FOMX: 5.97 (-0.04), GNST: (), GSK: 40.33 (-0.24), ALIM: 1.63 (unch), ALXN: 125.20 (-2.29), CBIO: 1.60 (+0.05), NVS: 77.91 (+1.02)
World Hepatitis B Therapeutics Pipeline Review 2015
M2 - Mon Jan 18, 6:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/5mxq4b/hepatitis_b) has announced the addition of the "Hepatitis B - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hepatitis B Overview - Therapeutics Development - Pipeline Products for Hepatitis B - Overview - Pipeline Products for Hepatitis B - Comparative Analysis - Hepatitis B - Therapeutics under Development by Companies - Hepatitis B - Therapeutics under Investigation by Universities/Institutes - Hepatitis B - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hepatitis B - Products under Development by Companies - Hepatitis B - Products under Investigation by Universities/Institutes - Hepatitis B - Companies Involved in Therapeutics Development- 35 of the 80 Companies Featured - Abivax S.A. - AiCuris GmbH & Co. KG - AIMM Therapeutics B.V. - Akshaya Bio Inc. - Alnylam Pharmaceuticals, Inc. - AlphaMab Co., Ltd - Altimmune, Inc. - AltraVax Inc. - Amarna Therapeutics B.V. - Arbutus Biopharma Corporation - Arrowhead Research Corporation - Assembly Biosciences, Inc. - Beijing Minhai Biotechnology Co., Ltd - Benitec Biopharma Limited - BioDiem Ltd - Biogenomics Limited - Biological E. Limited - BioStar Pharmaceuticals, Inc. - Bolder Biotechnology, Inc. - Bukwang Pharm.Co., Ltd. - CaroGen Corporation - CEL-SCI Corporation - Celltrion, Inc. - Chimerix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - ChronTech Pharma AB - Cocrystal Pharma, Inc. - Cytos Biotechnology AG - CyTuVax B.V. - Dong-A ST Co., Ltd. - Dynavax Technologies Corporation - Ensemble Therapeutics Corporation - Enyo Pharma S.A.S. - F. Hoffmann-La Roche Ltd. - GeneCure LLC For more information visit http://www.researchandmarkets.com/research/5m...epatitis_b
DVAX: 14.27 (-0.24), ABUS: 3.30 (+0.02), BSPM: 5.77 (+0.30), CMRX: 3.72 (-0.14), CVM: 0.46 (-0.01), ARWR: 5.74 (-0.19), ASMB: 6.26 (+0.27)
Greg West, Benitec's Chief Financial Officer and Company Secretary, Named Interim Chief Executive Officer
PR Newswire - Tue Dec 08, 4:05PM CST
The Board of Directors of Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) has today announced that Dr. Peter French will step down as Chief Executive Officer and Managing Director of the Company. Mr. Greg West, Benitec's Chief Financial Officer and Company Secretary, has been appointed as interim Chief Executive Officer.
Benitec's Hepatitis B Therapeutic Shows Positive Preclinical Results
PR Newswire - Mon Dec 07, 7:00AM CST
Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC) is pleased to announce that initial in vitro data demonstrates efficacy of BB-HB-331, a DNA directed RNA interference (ddRNAi)-based therapeutic designed to treat and potentially cure hepatitis B with a single injection. The data was presented at the HEP DART 2015 conference on December 6, 2015 (US time). Collectively, the positive data strongly supports progression of BB-HB-331 into in vivo testing.
Benitec Biopharma's Abstract Accepted for Presentation at the AASLD Liver Meeting 2015
PR Newswire - Thu Oct 22, 7:00AM CDT
Benitec Biopharma Limited (NASDAQ: BNTC; NASDAQ: BNTCW; ASX: BLT) is pleased to announce that clinical data on its Phase I/IIa study of TT-034 for hepatitis C will be presented in the 'late-breaking poster' session at The Liver Meeting® 2015, the 66th Annual Meeting of the American Association for the Study of Liver Disease (AASLD) being held in San Francisco on November 13-17, 2015.
Benitec Forms Hepatology Clinical Advisory Board
PR Newswire - Mon Oct 19, 6:30AM CDT
Benitec Biopharma Limited (NASDAQ: BNTC; ASX: BLT), a clinical-stage biotechnology company developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi or 'expressed RNAi', today announced the formation of its Hepatology Clinical Advisory Board. The newly appointed Clinical Advisory Board will serve as a strategic resource to Benitec as it continues to develop therapies for the treatment of hepatitis B and C.
Benitec Biopharma to Present at The 14th Annual BIO Investor Forum
PR Newswire - Wed Oct 14, 7:00AM CDT
Benitec Biopharma (ASX: BLT; NASDAQ: BNTC), a clinical-stage biotechnology company developing innovative therapeutics based on its gene silencing technology, DNA-directed RNA interference (ddRNAi), today announced that it will present at The 14th Annual BIO Investor Forum to be held October 20-21, 2015 at the Parc 55 San Francisco.
Benitec Biopharma Limited (Nasdaq: BNTC) to Ring The Nasdaq Stock Market Opening Bell
GlobeNewswire - Thu Sep 24, 9:00AM CDT
What:
BNTC: 1.33 (-0.03), BNTCW: 0.50 (unch), NDAQ: 63.88 (-1.01), BLT: 10.00 (+0.02)
Benitec Featured at CHI's "Discovery On Target" Conference
PR Newswire - Wed Sep 23, 7:00AM CDT
Benitec Biopharma (ASX: BLT; NASDAQ: BNTCW, NASDAQ: BNTC), a clinical-stage biotechnology company developing innovative therapeutics based on its gene silencing technology, DNA-directed RNA interference (ddRNAi), today announced that Peter French, Ph.D., the Company's CEO and Managing Director, was invited to discuss Benitec's ddRNAi technology at The Cambridge Healthtech Institute's (CHI) 13th Annual Discovery on Target Conference in Boston, MA.
Benitec Initiates a Fourth Site in Hepatitis C Clinical Trial
PR Newswire - Wed Sep 16, 6:30AM CDT
Benitec Biopharma Limited (NASDAQ: BNTC; NASDAQ: BNTCW; ASX: BLT) a clinical-stage biotechnology company developing innovative therapeutics based on its gene-silencing technology, DNA-directed RNA interference (ddRNAi), is pleased to announce it has initiated a new site for its ongoing Phase 1/2a TT-034 trial at the Methodist Health System Clinical Research Institute in Dallas, Texas. The site has commenced pre-screening hepatitis C patients and is led by principal investigator Dr. Parvez Mantry, a gastroenterologist and hepatologist.
Non-Small Cell Lung Cancer - Pipeline Review, H1 2015
M2 - Thu Sep 10, 6:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lckl3z/nonsmall_cell) has announced the addition of the "Non-Small Cell Lung Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned Partial list of the 200 companies mentioned in this comprehensive report: - AB Science - Bayer AG - Benitec Biopharma - Calithera Biosciences - Daiichi Sankyo - Eagle Pharmaceuticals - F. Hoffmann-La Roche - Five Prime Therapeutics - GeneFrontier - Halozyme Therapeutics - HanAll Biopharma - Ignyta - Immune Design - Jeil Pharmaceutical - Jiangsu Hengrui Medicine - Kadmon - KAEL-GemVax - Mabion - MacroGenics - NanoCarrier - Natco Pharma - Omnitura Therapeutics - Oncobiologics - Panacea Biotec - Peregrine Pharmaceuticals - Qu Biologics - Reata Pharmaceuticals - Samyang - Sanofi - Taiho Pharmaceutical - Targovax - Ultimovacs - XBiotech USA - Zhejiang BetaPharma For more information, including full list of companies mentioned, please visit http://www.researchandmarkets.com/research/lc...small_cell
IMDZ: 9.74 (-0.47), CALA: 4.29 (-0.42), EGRX: 44.77 (-2.05), FPRX: 39.42 (-1.58)
Benitec Announces Closing Of An Initial Public Offering In The United States With Listing On NASDAQ
PR Newswire - Mon Aug 24, 6:30AM CDT
Benitec Biopharma Limited (NASDAQ: BNTC; NASDAQ: BNTCW; ASX: BLT), a clinical-stage biotechnology company, is pleased to announce the closing of its U.S. initial public offering of 1,500,000 American Depositary Shares (ADSs)1, representing 30,000,000 fully paid ordinary shares of Benitec, together with warrants to purchase 500,000 ADSs, representing 10,000,000 fully paid ordinary shares. Each ADS represents 20 ordinary shares of Benitec. Benitec has granted the underwriter a 45-day option to purchase up to an additional 225,000 ADSs and/or 75,000 warrants to purchase ADSs to cover over-allotments, if any. Simultaneously with the closing, Benitec issued and sold 75,000 warrants in connection with the underwriter's partial exercise of such option.
Benitec Biopharma Interim Report for the Nine Months Ended March 31, 2016
PR Newswire - Tue May 24, 3:45AM CDT
Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today lodged its Interim Report for the nine months ended March 31, 2016. The report includes the financial results and a review of operations for the period.
Benitec Biopharma to Host Corporate Update Conference Call
PR Newswire - Tue May 17, 4:00AM CDT
Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today announced that the Company will host a conference call and live audio webcast on Wednesday, 25 May 2016 at 8:00am AEST / Tuesday, 24 May 2016 at 6:00pm EDT, to provide its quarterly operational update. Interim CEO, Greg West, will provide an overview of Benitec's current and planned corporate and clinical activities.
Benitec to present at the ASGCT 2016 Annual Meeting
PR Newswire - Mon Apr 25, 7:30AM CDT
Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW), a biotechnology company developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi or 'expressed RNAi', today announced acceptance of five presentations at the 19th Annual Meeting of American Society of Gene and Cell Therapy (ASGCT) being held in Washington D.C. on May 4-7, 2016. The abstracts cover the scientific results from three of Benitec's programs: hepatitis B, OPMD and hepatitis C, with the key findings briefly summarised below.
Benitec's Hepatitis B Therapy Reduces HBV DNA by 98.5% In Vivo
PR Newswire - Tue Mar 08, 7:16AM CST
Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is pleased to announce that BB-HB-331, a DNA-directed RNA interference (ddRNAi) therapy targeting the hepatitis B virus (HBV), demonstrates robust and durable suppression of HBV in vivo following a single administration.
Neuropathic Pain Pipeline Review, H2 2015 - Therapeutics Developments from 100+ Companies
M2 - Tue Feb 09, 8:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/vlqwp7/neuropathic_pain) has announced the addition of the "Neuropathic Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuropathic Painand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Neuropathic PainOverview - Therapeutics Development - Pipeline Products for Neuropathic Pain- Overview - Pipeline Products for Neuropathic Pain- Comparative Analysis - Neuropathic Pain- Therapeutics under Development by Companies - Neuropathic Pain- Therapeutics under Investigation by Universities/Institutes - Neuropathic Pain- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Neuropathic Pain- Products under Development by Companies - Neuropathic Pain- Products under Investigation by Universities/Institutes - Neuropathic Pain- Companies Involved in Therapeutics Development Companies Mentioned - 2-BBB Medicines BV - AbbVie Inc. - Advinus Therapeutics Ltd. - Adynxx, Inc. - Aestus Therapeutics, Inc. - Affectis Pharmaceuticals AG - Allergan Plc - Amura Holdings Limited - AnaBios Corporation - Anavex Life Sciences Corp. - AngioChem Inc. - Asahi Kasei Pharma Corp. - Astellas Pharma Inc. - AstraZeneca Plc - BCN Peptides, S.A. - Benitec Biopharma Limited - BioDelivery Sciences International, Inc. - BioLineRx, Ltd. - Biomar Microbial Technologies - Bionomics Limited - Biscayne Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Can-Fite BioPharma Ltd. - Cara Therapeutics, Inc. - Catalyst Biosciences, Inc. - Cavion LLC - Cerecor Inc. - Circuit Therapeutics, Inc. - CLL Pharma - Colby Pharmaceutical Company - Convergence Pharmaceuticals Ltd. - Creabilis SA - Crinetics Pharmaceuticals, Inc. - Cytogel Pharma, LLC For more information visit http://www.researchandmarkets.com/research/vl...athic_pain
CANF: 2.62 (-0.16), BDSI: 2.39 (unch), AGN: 235.05 (-2.24), CERCU: 5.03 (-0.56), AVXL: 4.02 (-0.27), AZN: 27.58 (-0.05), CBIO: 1.60 (+0.05), ABBV: 60.01 (-0.89), BMY: 70.67 (-1.06)
Cancer Pain Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/3tjd78/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Cancer Pain Overview - Therapeutics Development - Pipeline Products for Cancer Pain - Overview - Pipeline Products for Cancer Pain - Comparative Analysis - Cancer Pain - Therapeutics under Development by Companies - Cancer Pain - Therapeutics under Investigation by Universities/Institutes - Cancer Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cancer Pain - Products under Development by Companies - Cancer Pain - Products under Investigation by Universities/Institutes - Cancer Pain - Companies Involved in Therapeutics Development - Amgen Inc. - Amorsa Therapeutics Inc. - AngioChem Inc. - Aphios Corporation - AstraZeneca Plc - BCN Peptides, S.A. - Benitec Biopharma Limited - BioDelivery Sciences International, Inc. - ChironWells GmbH - Daiichi Sankyo Company, Limited - Fujimoto Pharmaceutical Corporation - Grunenthal GmbH - GW Pharmaceuticals Plc - Hisamitsu Pharmaceutical Co., Inc. - Immupharma Plc - IntelGenx Corp. - Kolon Life Science, Inc. - Nektar Therapeutics - Neurocentrx Pharma Ltd. - Orion Oyj - Pain Therapeutics, Inc. - Pfizer Inc. - Pharmaleads - PsychoGenics, Inc. - Recordati S.p.A. - Ribomic Inc. - Virobay Inc. - WEX Pharmaceuticals Inc. - Winston Pharmaceuticals, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/3t...ancer_pain
BDSI: 2.39 (unch), PFE: 34.22 (-0.53), AMGN: 149.62 (-2.68), ZYNE: 7.55 (-0.24), NKTR: 14.85 (-0.17), AZN: 27.58 (-0.05), VBAY: (), PTIE: 2.03 (-0.06)
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review 2015
M2 - Fri Jan 29, 10:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfl587/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Wet (Neovascular / Exudative) Macular Degeneration Overview - Therapeutics Development - Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview - Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Comparative Analysis - Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies - Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes - Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies - Wet (Neovascular / Exudative) Macular Degeneration - Products under Investigation by Universities/Institutes - Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development Companies Mentioned: - Aciont Inc. - Allergan Plc - Amakem NV - Apellis Pharmaceuticals, Inc. - Apexigen, Inc. - Applied Genetic Technologies Corporatio - Avalanche Biotechnologies, Inc. - Benitec Biopharma Limited - BIOCAD - Boehringer Ingelheim GmbH - Charlesson LLC. - Chong Kun Dang Pharmaceutical Corp. - Circadian Technologies Limited - Clanotech AB - Clearside BioMedical, Inc. - Daiichi Sankyo Company, Limited - Eleven Biotherapeutics Inc. - Exonate Limited - F. Hoffmann-La Roche Ltd. - Formycon AG - GTx, Inc. - iCo Therapeutics Inc. - Icon Bioscience, Inc. - Kala Pharmaceuticals, Inc. - Mabion SA - Mitotech S.A. - Neurotech Pharmaceuticals, Inc. - Novartis AG - Ocular Therapeutix, Inc. - Ohr Pharmaceutical Inc. - Ophthotech Corp. - Oxford BioMedica Plc - PanOptica, Inc. - Pfenex Inc. - Pfizer Inc. - Quark Pharmaceuticals, Inc. - Regeneron Pharmaceuticals, Inc. - RegenxBio Inc. - RXi Pharmaceuticals Corporation - Santen Pharmaceutical Co., Ltd. - Sanwa Kagaku Kenkyusho Co., Ltd. - TRACON Pharmaceuticals, Inc. - TWi Pharmaceuticals, Inc. - Tyrogenex, Inc. - Xbrane Bioscience AB For more information visit http://www.researchandmarkets.com/research/rf...eovascular
CLSD: 7.10 (+0.10), PFE: 34.22 (-0.53), OPHT: 52.79 (-2.13), PFNX: 8.02 (-0.08), OCUL: 5.40 (-0.19), AGN: 235.05 (-2.24), GTXI: 0.61 (-0.02), OHRP: 2.68 (-0.12), AAVL: 4.14 (-0.18), TCON: 5.03 (-0.22), REGN: 354.21 (-12.31), NVS: 77.91 (+1.02)
Dry (Atrophic) Macular Degeneration therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 6:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/3cxkl2/dry_atrophic) has announced the addition of the "Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dry (Atrophic) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dry (Atrophic) Macular Degeneration Overview - Therapeutics Development - Pipeline Products for Dry (Atrophic) Macular Degeneration - Overview - Pipeline Products for Dry (Atrophic) Macular Degeneration - Comparative Analysis - Dry (Atrophic) Macular Degeneration - Therapeutics under Development by Companies - Dry (Atrophic) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes - Dry (Atrophic) Macular Degeneration - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Dry (Atrophic) Macular Degeneration - Products under Development by Companies - Dry (Atrophic) Macular Degeneration - Products under Investigation by Universities/Institutes - Dry (Atrophic) Macular Degeneration - Companies Involved in Therapeutics Development - Aciont Inc. - Acucela Inc. - Alexion Pharmaceuticals, Inc. - Alimera Sciences, Inc. - Apellis Pharmaceuticals, Inc. - Benitec Biopharma Limited - Catalyst Biosciences, Inc. - Cell Cure Neurosciences, Ltd. - Foamix Pharmaceuticals Ltd. - Genentech, Inc. - GenSight Biologics SA - GlaxoSmithKline Plc - Icon Bioscience, Inc. - MacuCLEAR, Inc. - Novartis AG - Ocata Therapeutics, Inc. - Ophthotech Corp. - pSivida Corp. - R-Tech Ueno, Ltd. - StemCells, Inc. - Sun Pharma Advanced Research Company Ltd. - U.S. Stem Cell, Inc. For more information visit http://www.researchandmarkets.com/research/3c...y_atrophic
OCAT: 8.47 (+0.01), OPHT: 52.79 (-2.13), FOMX: 5.97 (-0.04), GNST: (), GSK: 40.33 (-0.24), ALIM: 1.63 (unch), ALXN: 125.20 (-2.29), CBIO: 1.60 (+0.05), NVS: 77.91 (+1.02)
World Hepatitis B Therapeutics Pipeline Review 2015
M2 - Mon Jan 18, 6:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/5mxq4b/hepatitis_b) has announced the addition of the "Hepatitis B - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hepatitis B Overview - Therapeutics Development - Pipeline Products for Hepatitis B - Overview - Pipeline Products for Hepatitis B - Comparative Analysis - Hepatitis B - Therapeutics under Development by Companies - Hepatitis B - Therapeutics under Investigation by Universities/Institutes - Hepatitis B - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hepatitis B - Products under Development by Companies - Hepatitis B - Products under Investigation by Universities/Institutes - Hepatitis B - Companies Involved in Therapeutics Development- 35 of the 80 Companies Featured - Abivax S.A. - AiCuris GmbH & Co. KG - AIMM Therapeutics B.V. - Akshaya Bio Inc. - Alnylam Pharmaceuticals, Inc. - AlphaMab Co., Ltd - Altimmune, Inc. - AltraVax Inc. - Amarna Therapeutics B.V. - Arbutus Biopharma Corporation - Arrowhead Research Corporation - Assembly Biosciences, Inc. - Beijing Minhai Biotechnology Co., Ltd - Benitec Biopharma Limited - BioDiem Ltd - Biogenomics Limited - Biological E. Limited - BioStar Pharmaceuticals, Inc. - Bolder Biotechnology, Inc. - Bukwang Pharm.Co., Ltd. - CaroGen Corporation - CEL-SCI Corporation - Celltrion, Inc. - Chimerix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - ChronTech Pharma AB - Cocrystal Pharma, Inc. - Cytos Biotechnology AG - CyTuVax B.V. - Dong-A ST Co., Ltd. - Dynavax Technologies Corporation - Ensemble Therapeutics Corporation - Enyo Pharma S.A.S. - F. Hoffmann-La Roche Ltd. - GeneCure LLC For more information visit http://www.researchandmarkets.com/research/5m...epatitis_b
DVAX: 14.27 (-0.24), ABUS: 3.30 (+0.02), BSPM: 5.77 (+0.30), CMRX: 3.72 (-0.14), CVM: 0.46 (-0.01), ARWR: 5.74 (-0.19), ASMB: 6.26 (+0.27)
Greg West, Benitec's Chief Financial Officer and Company Secretary, Named Interim Chief Executive Officer
PR Newswire - Tue Dec 08, 4:05PM CST
The Board of Directors of Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) has today announced that Dr. Peter French will step down as Chief Executive Officer and Managing Director of the Company. Mr. Greg West, Benitec's Chief Financial Officer and Company Secretary, has been appointed as interim Chief Executive Officer.
Benitec's Hepatitis B Therapeutic Shows Positive Preclinical Results
PR Newswire - Mon Dec 07, 7:00AM CST
Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC) is pleased to announce that initial in vitro data demonstrates efficacy of BB-HB-331, a DNA directed RNA interference (ddRNAi)-based therapeutic designed to treat and potentially cure hepatitis B with a single injection. The data was presented at the HEP DART 2015 conference on December 6, 2015 (US time). Collectively, the positive data strongly supports progression of BB-HB-331 into in vivo testing.
Benitec Biopharma's Abstract Accepted for Presentation at the AASLD Liver Meeting 2015
PR Newswire - Thu Oct 22, 7:00AM CDT
Benitec Biopharma Limited (NASDAQ: BNTC; NASDAQ: BNTCW; ASX: BLT) is pleased to announce that clinical data on its Phase I/IIa study of TT-034 for hepatitis C will be presented in the 'late-breaking poster' session at The Liver Meeting® 2015, the 66th Annual Meeting of the American Association for the Study of Liver Disease (AASLD) being held in San Francisco on November 13-17, 2015.
Benitec Forms Hepatology Clinical Advisory Board
PR Newswire - Mon Oct 19, 6:30AM CDT
Benitec Biopharma Limited (NASDAQ: BNTC; ASX: BLT), a clinical-stage biotechnology company developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi or 'expressed RNAi', today announced the formation of its Hepatology Clinical Advisory Board. The newly appointed Clinical Advisory Board will serve as a strategic resource to Benitec as it continues to develop therapies for the treatment of hepatitis B and C.
Benitec Biopharma to Present at The 14th Annual BIO Investor Forum
PR Newswire - Wed Oct 14, 7:00AM CDT
Benitec Biopharma (ASX: BLT; NASDAQ: BNTC), a clinical-stage biotechnology company developing innovative therapeutics based on its gene silencing technology, DNA-directed RNA interference (ddRNAi), today announced that it will present at The 14th Annual BIO Investor Forum to be held October 20-21, 2015 at the Parc 55 San Francisco.
Benitec Biopharma Limited (Nasdaq: BNTC) to Ring The Nasdaq Stock Market Opening Bell
GlobeNewswire - Thu Sep 24, 9:00AM CDT
What:
BNTC: 1.33 (-0.03), BNTCW: 0.50 (unch), NDAQ: 63.88 (-1.01), BLT: 10.00 (+0.02)
Benitec Featured at CHI's "Discovery On Target" Conference
PR Newswire - Wed Sep 23, 7:00AM CDT
Benitec Biopharma (ASX: BLT; NASDAQ: BNTCW, NASDAQ: BNTC), a clinical-stage biotechnology company developing innovative therapeutics based on its gene silencing technology, DNA-directed RNA interference (ddRNAi), today announced that Peter French, Ph.D., the Company's CEO and Managing Director, was invited to discuss Benitec's ddRNAi technology at The Cambridge Healthtech Institute's (CHI) 13th Annual Discovery on Target Conference in Boston, MA.
Benitec Initiates a Fourth Site in Hepatitis C Clinical Trial
PR Newswire - Wed Sep 16, 6:30AM CDT
Benitec Biopharma Limited (NASDAQ: BNTC; NASDAQ: BNTCW; ASX: BLT) a clinical-stage biotechnology company developing innovative therapeutics based on its gene-silencing technology, DNA-directed RNA interference (ddRNAi), is pleased to announce it has initiated a new site for its ongoing Phase 1/2a TT-034 trial at the Methodist Health System Clinical Research Institute in Dallas, Texas. The site has commenced pre-screening hepatitis C patients and is led by principal investigator Dr. Parvez Mantry, a gastroenterologist and hepatologist.
Non-Small Cell Lung Cancer - Pipeline Review, H1 2015
M2 - Thu Sep 10, 6:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lckl3z/nonsmall_cell) has announced the addition of the "Non-Small Cell Lung Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned Partial list of the 200 companies mentioned in this comprehensive report: - AB Science - Bayer AG - Benitec Biopharma - Calithera Biosciences - Daiichi Sankyo - Eagle Pharmaceuticals - F. Hoffmann-La Roche - Five Prime Therapeutics - GeneFrontier - Halozyme Therapeutics - HanAll Biopharma - Ignyta - Immune Design - Jeil Pharmaceutical - Jiangsu Hengrui Medicine - Kadmon - KAEL-GemVax - Mabion - MacroGenics - NanoCarrier - Natco Pharma - Omnitura Therapeutics - Oncobiologics - Panacea Biotec - Peregrine Pharmaceuticals - Qu Biologics - Reata Pharmaceuticals - Samyang - Sanofi - Taiho Pharmaceutical - Targovax - Ultimovacs - XBiotech USA - Zhejiang BetaPharma For more information, including full list of companies mentioned, please visit http://www.researchandmarkets.com/research/lc...small_cell
IMDZ: 9.74 (-0.47), CALA: 4.29 (-0.42), EGRX: 44.77 (-2.05), FPRX: 39.42 (-1.58)
Benitec Announces Closing Of An Initial Public Offering In The United States With Listing On NASDAQ
PR Newswire - Mon Aug 24, 6:30AM CDT
Benitec Biopharma Limited (NASDAQ: BNTC; NASDAQ: BNTCW; ASX: BLT), a clinical-stage biotechnology company, is pleased to announce the closing of its U.S. initial public offering of 1,500,000 American Depositary Shares (ADSs)1, representing 30,000,000 fully paid ordinary shares of Benitec, together with warrants to purchase 500,000 ADSs, representing 10,000,000 fully paid ordinary shares. Each ADS represents 20 ordinary shares of Benitec. Benitec has granted the underwriter a 45-day option to purchase up to an additional 225,000 ADSs and/or 75,000 warrants to purchase ADSs to cover over-allotments, if any. Simultaneously with the closing, Benitec issued and sold 75,000 warrants in connection with the underwriter's partial exercise of such option.
